Our achievements

Merz Therapeutics acquires two marketed products: levodopa inhalation powder for treating “OFF episodes” for people living with Parkinson’s disease and dalfampridine for improved walking for people living with multiple sclerosis. Adding these assets to our treatment portfolio is part of our acquisition strategy, intended to increase our scale and global reach so we can deliver better outcomes for more patients.

• Our partner in Japan, Teijin Pharma, receives approval to market botulinum neurotoxin type A for the treatment of lower limb spasticity in adults
• EU approval for the symptomatic treatment 
of chronic sialorrhea due to neurological / neurodevelopmental disorders in children and adolescents age 2 to 17
• Merz and the Israeli start-up Vensica launch strategic partnership for the needleless treatment of overactive bladder delivering Botulinum neurotoxin type A to the bladder wall by using Vensica’s innovative ultrasound-assisted 
delivery catheter

• Our partner in Japan, Teijin Pharma, receives approval to market botulinum neurotoxin type A for the treatment of upper limb spasticity in adults
• US approval for the treatment of upper limb spasticity in pediatric patients age 2 to 17, excluding spasticity caused by cerebral palsy
• US approval for the treatment of chronic sialorrhea in patients age 2 and older. The first neurotoxin on the market to treat pediatric patients suffering from sialorrhea

Start of Merz Therapeutics as a dedicated company within the Merz Group committed to serving the unmet needs of patients suffering from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life.

• EU approval for the treatment of chronic sialorrhea in adults
• US approval for first-line treatment of adults with blepharospasm
• EU approval for the symptomatic treatment of hemifacial spasm in adults

US approval for the treatment of adults with 
chronic sialorrhea

US approval for the treatment of adult patients with upper limb spasticity

Proven injectable implants indicated for the treatment of vocal fold insufficiency, providing both short-term and long-term options for patients 
in a single portfolio

US approval for the treatment of chronic severe drooling in pediatric patients with neurological conditions, the only liquid formulation on the market, designed with the aim to deliver an individualized dose for patients

US approval for the treatment of adults with cervical dystonia and blepharospasm (pre-treated with onabotulinumtoxina)

EU approval for the treatment of post-stroke upper limb spasticity in adults

German approval for the treatment 
of blepharospasm and cervical dystonia in adults

First active compound worldwide for the treatment 
of moderate to severe Alzheimer’s disease

Oral hair and nail therapeutic agent for the treatment of various forms of diffuse hair loss and improvement in hair growth, hair damaged by sunlight and UV radiation and nail growth disorders

For the treatment of symptoms of Parkinson‘s disease, such as rigor, tremor and hypo or akinesia, drug-induced extrapyramidal symptoms such 
as early dyskinesia, akathisia, and 
parkinsonoid syndrome

For the treatment of chronic liver diseases with insufficient hepatic detoxification (e.g. in liver cirrhosis) and its complications 
(hepatic encephalopathy)

Prevention of scars, for fresh or older scars and keloids, promoting the normal wound healing process, anti-inflammatory, anti-redness, reducing swelling, pain and irritation